Il-6 Involvement in pain, fatigue and mood disorders in rheumatoid arthritis and the effects of Il-6 inhibitor sarilumab.

Szczegóły
Abstrakt

Tytuł:: Il-6 Involvement in pain, fatigue and mood disorders in rheumatoid arthritis and the effects of Il-6 inhibitor sarilumab.
Autorzy:: Atzeni F; Rheumatology Unit, University of Messina, Messina, Italy. Electronic address: .
Nucera V; Rheumatology Unit, University of Messina, Messina, Italy.
Masala IF; Trauma and Orthopedic Unit, Santissima Trinità Hospital, Cagliari, Italy.
Sarzi-Puttini P; Rheumatology Unit, L. Sacco University Hospital, Milan, Italy.
Bonitta G; Department of Biomedical Science for Health, University of Milan, Istituto Clinico Sant'Ambrogio, Milan, Italy.
Źródło:: Pharmacological research [Pharmacol Res] 2019 Nov; Vol. 149, pp. 104402. Date of Electronic Publication: 2019 Sep 16.
Typ publikacji:: Journal Article; Review
Język:: English
Imprint Name(s):: Publication: Oct. 2015- : Amsterdam ; Elsevier
Original Publication: London ; San Diego : Academic Press, c1989-
MeSH Terms:: Antibodies, Monoclonal, Humanized/*therapeutic use
Arthritis, Rheumatoid/*drug therapy
Fatigue/*drug therapy
Interleukin-6/*antagonists & inhibitors
Mood Disorders/*drug therapy
Pain/*drug therapy
Arthritis, Rheumatoid/complications ; Arthritis, Rheumatoid/immunology ; Fatigue/complications ; Fatigue/immunology ; Humans ; Male ; Mood Disorders/complications ; Mood Disorders/immunology ; Pain/complications ; Pain/immunology ; Randomized Controlled Trials as Topic ; Treatment Outcome
Contributed Indexing:: Keywords: IL-6; Rheumatoid arthritis; Sarilumab
Substance Nomenclature:: 0 (Antibodies, Monoclonal, Humanized)
0 (Interleukin-6)
NU90V55F8I (sarilumab)
Entry Date(s):: Date Created: 20190920 Date Completed: 20200504 Latest Revision: 20200505
Update Code:: 20240105
DOI:: 10.1016/j.phrs.2019.104402
PMID:: 31536783
: Czasopismo naukowe

Interleukin 6 (IL-6) is a pleiotropic cytokine that plays a role in the neuroendocrine system, insulin resistance, lipid metabolism, vascular disease, mitochondrial activities, neuropsychological behaviour, and also mediates communications between the immune and central nervous system (CNS). Treatment with anti-IL-6 or anti-IL-6R agents seems to alleviate allodynia and hyperalgesia, so it may be a valid option when treating the many conditions involving pathological pain as rheumatoid arthritis.
(Copyright © 2019 Elsevier Ltd. All rights reserved.)

Informacja